Palo Alto Investors LP Invests $36.59 Million in Dyne Therapeutics, Inc. $DYN

Posted by Brenda Bartman on Aug 28th, 2026

Palo Alto Investors LP bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,647,521 shares of the company’s stock, valued at approximately $36,591,441. Dyne Therapeutics comprises about 0.0% of Palo Alto Investors LP’s portfolio, making the stock its 7th biggest position. Palo Alto Investors LP owned approximately 0.88% of Dyne Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of DYN. T. Rowe Price Investment Management Inc. increased its holdings in shares of Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. BlackRock Inc. bought a new position in shares of Dyne Therapeutics during the second quarter valued at $275,500,000. Jupiter Topco LLC bought a new position in shares of Dyne Therapeutics in the second quarter worth approximately $266,634,000. Orbis Allan Gray Ltd purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at approximately $93,926,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Dyne Therapeutics during the second quarter worth about $30,378,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares in the company, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the transaction, the chief financial officer owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 4,139,196 shares of company stock valued at $99,449,852. Corporate insiders own 9.46% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN traded down $1.02 during trading on Friday, reaching $25.07. 1,186,929 shares of the company traded hands, compared to its average volume of 2,067,894. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31. The firm has a market capitalization of $4.68 billion, a PE ratio of -7.53 and a beta of 1.07. The company’s 50 day moving average is $24.26 and its two-hundred day moving average is $20.02. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DYN. Sanford C. Bernstein upped their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Wall Street Zen downgraded Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Cantor Fitzgerald started coverage on shares of Dyne Therapeutics in a research report on Thursday, July 23rd. They set an “overweight” rating for the company. TD Cowen initiated coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.42.

Read Our Latest Stock Report on DYN

Dyne Therapeutics Company Profile

(Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.